- Docket Number:
- Issued by:
Guidance Issuing OfficeCenter for Food Safety and Applied Nutrition
Office of Food Safety
Division of Seafood Safety HFS-325
Center for Food Safety and Applied Nutrition
Food and Drug Administration
5001 Campus Drive
College Park, MD 20740
This guidance represents the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations.
Table of Contents
The purpose of this letter is to provide guidance to industry. The letter sets forth FDA's policy concerning the fraudulent practice of including glaze (ice) as part of the weight of frozen seafood.
FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidances means that something is suggested or recommended, but not required.
This letter was initially issued to the seafood industry in 1991, and we are putting it on our guidance page for ease of accessibility.
FDA has received information about recent increases in electronic solicitations offering to sell seafood products at less than 100% net weight (i.e. - seafood products that may include the weight of the glazing (ice) in the net weight). This letter should serve as a reminder to the entire seafood industry of our policy regarding the fraudulent practice of including glaze (ice) as part of the weight of frozen seafood.
Although the policy set forth in this letter does reflect FDA's current policy regarding this issue, the contact information has changed (see section IV below).
III. The 1991 Letter
June 4, 1991
Dear Seafood Manufacturer:
The Food and Drug Administration (FDA) is, by this 1etter, warning members of the frozen seafood industry that the net weight of frozen seafood may not include the weight of glazing (ice). FDA has received a number of complaints from seafood trade associations, the seafood industry and other Federal agencies concerning recent increases in the fraudulent practice of including glaze (ice) as part of the weight of frozen seafood such as shrimp, lobster, and fish fillets.
Section 402(b) of the Federal Food Drug and Cosmetic Act (FD&C Act) prohibits the adulteration of food by adding any substance (such as ice glaze) to increase its bulk or weight. Section 403(e)(2) of the FD&C Act and section 4(a)(2) of the Fair Packaging and Labeling Act require food to bear an accurate statement of the net quantity of contents. Overstating the net quantity of contents (such as including the weight of ice glaze) misbrands the products under these sections. Violations of this kind may be criminally prosecuted under the FD&C Act as felonies since they are committed with the intent to defraud or mislead.
We request that you take prompt action to assure that any frozen seafood you sell does not include the weight of the glaze in the net weight. Failure to promptly correct any such violations can result in regulatory action such as detention, seizure, injunction or criminal prosecution being initiated by the Food and Drug Administration without any further notice to you.
If you have any questions regarding this matter, they should be directed to the Food and Drug Administration, Mr. Martin Stutsman at current contact information.
IV. Current Contact Information
Any questions regarding this matter should be directed to the Director of the Division of Seafood Safety in FDA's Office of Food Safety at 240-402-2300.
You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
If unable to submit comments online, please mail written comments to:
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: FDA-2020-D-1923.